Spots Global Cancer Trial Database for platinum resistant
Every month we try and update this database with for platinum resistant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04781088 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Lenvatinib Paclitaxel Pembrolizumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | NCT03608618 | Peritoneal Meso... Fallopian Tube ... Adenocarcinoma ... Primary Periton... | MCY-M11 Cyclophosphamid... | 18 Years - | MaxCyte, Inc. | |
| Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer | NCT02399592 | Ovarian Cancer | Bevacizumab Tocotrinol | 18 Years - | Vejle Hospital | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | NCT01644825 | Ovarian Cancer | paclitaxel pazopanib | 18 Years - 75 Years | National Cancer Institute, Naples | |
| Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | NCT00477386 | Ovarian Cancer | decitabine | 18 Years - | Indiana University | |
| Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | NCT04729608 | Platinum-resist... | Batiraxcept Paclitaxel Placebo | 18 Years - | Aravive, Inc. | |
| Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer | NCT05272462 | Ovarian Cancer | Minoxidil | 18 Years - 90 Years | Loyola University | |
| "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01883297 | Recurrent Platinum-resist... High Grade Sero... Fallopian Tube ... Primary Periton... | Re-stimulated t... Interleukin-2 Cyclophosphamid... | 18 Years - | University Health Network, Toronto | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | NCT02580058 | Ovarian Cancer | avelumab PLD | 18 Years - | Pfizer | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| Use of Regorafenib in Recurrent Epithelial Ovarian Cancer | NCT02736305 | Ovarian Neoplas... | Regorafenib | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | NCT03648489 | Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Ovarian Serous ... Ovarian Endomet... Ovarian Clear C... Fallopian Tube ... Fallopian Tube ... Primary Periton... Primary Periton... | Paclitaxel TAK228 | 18 Years - | Imperial College London | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | NCT04846842 | Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Gimatecan | 18 Years - | Lee's Pharmaceutical Limited | |
| Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | NCT03639246 | Ovarian Cancer | AVB-S6-500 Paclitaxel (Pac... Pegylated lipos... Placebo | 18 Years - | Aravive, Inc. | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | NCT06305299 | Ovary Neoplasm Ovarian Cancer Epithelial Ovar... Recurrent | iC9-CAR.B7-H3 T... Cyclophosphamid... Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC | NCT03363867 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Atezolizumab Bevacizumab Cobimetinib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer | NCT02399592 | Ovarian Cancer | Bevacizumab Tocotrinol | 18 Years - | Vejle Hospital | |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | NCT02580058 | Ovarian Cancer | avelumab PLD | 18 Years - | Pfizer | |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC | NCT03363867 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Atezolizumab Bevacizumab Cobimetinib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type | NCT00861120 | Epithelial Ovar... | Pegylated lipos... Panitumumab | 18 Years - | Vejle Hospital | |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | NCT04296890 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... | 18 Years - | ImmunoGen, Inc. | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | NCT02195973 | Recurrent Ovari... | LDE225 | 19 Years - | University of Alabama at Birmingham | |
| PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | NCT00059618 | Ovarian Cancer Primary Periton... Fallopian Tube ... | PS-341 (Bortezo... Carboplatin | - | M.D. Anderson Cancer Center | |
| Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer | NCT00408603 | Epithelial Ovar... | Voreloxin Injec... | 18 Years - | Sunesis Pharmaceuticals | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer | NCT01608009 | Ovarian Neoplas... | Pazopanib and p... | 18 Years - | Imperial College London | |
| Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer | NCT05156892 | Ovarian Cancer | SUBA-itraconazo... Tamoxifen | 18 Years - | St Vincent's Hospital, Sydney | |
| Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | NCT03949283 | Recurrent Ovari... Platinum-resist... | ChemoID Assay Standard Chemot... | 18 Years - | Cordgenics, LLC | |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT03907527 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... | PRGN-3005 Ultra... PRGN-3005 Ultra... | 18 Years - | Precigen, Inc | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | NCT05407584 | PARP Inhibitor ... | Orevogomab+PLD Orevogomab+Pacl... | 20 Years - | Yonsei University | |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | NCT03648489 | Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Ovarian Serous ... Ovarian Endomet... Ovarian Clear C... Fallopian Tube ... Fallopian Tube ... Primary Periton... Primary Periton... | Paclitaxel TAK228 | 18 Years - | Imperial College London | |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | NCT04296890 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... | 18 Years - | ImmunoGen, Inc. | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | NCT02759588 | Ovarian Cancer Peritoneal Carc... Fallopian Tube ... | GL-ONC1 alone, ... | 21 Years - | Genelux Corporation | |
| Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | NCT01644825 | Ovarian Cancer | paclitaxel pazopanib | 18 Years - 75 Years | National Cancer Institute, Naples | |
| PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | NCT00059618 | Ovarian Cancer Primary Periton... Fallopian Tube ... | PS-341 (Bortezo... Carboplatin | - | M.D. Anderson Cancer Center | |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | NCT00913835 | Ovarian Neoplas... | Olaratumab liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer | NCT05156892 | Ovarian Cancer | SUBA-itraconazo... Tamoxifen | 18 Years - | St Vincent's Hospital, Sydney |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
